drugset / Trial / NCT05429632
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Timeline
- Start
- 2022-06-16
- Primary completion
- 2027-05
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mocravimod | Small molecule | 1 mg | Oral |
| Subject | mocravimod | Small molecule | 3 mg | Oral |